Lead Product(s): Zotatifin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Preclinical evaluation results of eFT226 showed that zotatifin significantly inhibited tumor growth and caused tumor regression across diverse RTK-driven tumor types.